Skip to content

Pneumoperitoneum Management With SurgiQuest AirSeal at Low vs. Higher Pressure ( PRESSURE )

A Single Center, Prospective, Randomized, Controlled Study To Evaluate Physician Preference Related to the Use of the SURGIQUEST AIRSEAL® INSUFFLATION SYSTEM (AIS) at Low VS. Higher Pressure for the Management of Pneumoperitoneum.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02541448
Acronym
PRESSURE
Enrollment
119
Registered
2015-09-04
Start date
2015-07-31
Completion date
2018-07-12
Last updated
2019-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder Pain

Brief summary

This study is designed to evaluate physician preference related to the use of the SURGIQUEST AIRSEAL® INSUFFLATION SYSTEM (AIS) at low verses high pressure for the management of pneumoperitoneum.

Detailed description

The objective of this study is to evaluate physician preferences related to use of the SurgiQuest AirSeal Insufflation System (AIS) used at low vs. higher pressures for maintaining pneumoperitoneum during laparoscopic/robotic surgical procedures. The study is designed and powered to demonstrate superiority of the AIS used at low insufflation pressure (9±mmHg ±1mmHg) vs higher pressure (15mmHg ±1mmHg) in relation to a single key effectiveness measure: Incidence of shoulder pain. Patients will be randomized 1:1 to either AIS with an insufflation pressure target of 9±1mmHg) or to AIS with an insufflation target pressure of 15±1mmHg. Secondary outcome measures include severity of shoulder pain measured using a VAS scale and medication use, procedure time, the number of procedure interruptions, length of hospital stay, aspects of anesthesia management including end tidal CO2 and the frequency of adverse events. These outcomes will be evaluated in a controlled population undergoing laparoscopic/robotic surgery.

Interventions

DEVICESurgiQuest AIRSEAL® Insufflation System (AIS)

The SurgiQuest AirSeal Optical Trocar & Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization.

Sponsors

SurgiQuest, Inc.
CollaboratorINDUSTRY
Cynthia Harris
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. 18 to 80 years of age; 2. Capable and willing to give informed consent; 3. Acceptable candidate for an elective, non-emergent laparoscopic/robotic surgery;

Exclusion criteria

1. Advanced refusal of blood transfusion, if necessary; 2. Active systemic or cutaneous infection or inflammation; 3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids; 4. Uncontrolled diabetes mellitus 5. Known, significant history of bleeding diathesis, coagulopathy, Von Willebrand's disease or current platelet count \< 100,000 cells/mm3, baseline INR ≥1.8, or fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24 hours); 6. Severe co-existing morbidities having a life expectancy of less than 30 days; 7. Currently involved in any other investigational clinical Studies; 8. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than 30%; 9. Renal insufficiency (serum creatinine of \> 2.5 mg/dl); 10. Females who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating; 11. Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than 20 kg/m2); 12. Patients presenting with Ascites -

Design outcomes

Primary

MeasureTime frameDescription
Incidence of shoulder painparticipants will be followed for the duration of hospital stay, an expected average of 24 hoursIncidence of reported shoulder pain

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026